Skip to main content
Fig. 1 | BMC Microbiology

Fig. 1

From: Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020

Fig. 1

Relebactam restores/enhances the activity of imipenem in Pseudomonas aeruginosa isolates. A all (N = 23,073). B imipenem-NS (N = 8356). C imipenem-S (N = 14,717). Percentage represents n/N × 100%, where n was the number of isolates meeting the MIC threshold and N was the total number of isolates based on the CLSI 2021 clinical breakpoints for imipenem/relebactam (MIC ≤ 2 μg/mL for susceptibility) and subsequently categorized as either S (MIC ≤ 2 μg/mL) or NS (MIC > 2 μg/mL) [18]. The dashed line indicates the CLSI 2021 imipenem/relebactam susceptibility breakpoints. The arrows indicate mode MIC values. CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration; NS, nonsusceptible; S, susceptible

Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us